Clinical Trial Update: A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase IIa clinical trial update for Purinostat Mesylate for Injection in relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma, with t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Purinostat Mesylate (Purinostat Mesylate)

Snippet

Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd | Conditions: Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING